Fig. 3.

Molecular docking of dihydrocanaric acid, betulinic acid, doxorubicin with estrogen receptor (ER) (PDB, 2IOK), epidermal growth factor (EGFR) (PDB, 1IVO), human androgen receptor (PDB, 2AO6), Phosphoinositide 3-kinase (PI3K) (PDB, 4FLH), Estrogen receptor alpha (PDB, IXPC) and uPAR (PDB, IYWH)